Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to AnalyticsAdvancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics

This webcast features: Shanshan Wang, PhD, associate director, Innoforce Pharmaceuticals.

The therapeutic potential of mRNA-based therapies is rapidly being recognized across various fields, positioning the mRNA sector as a fast-emerging area of innovation. Beyond conventional mRNA, circular RNA (circRNA) and self-amplifying RNA (saRNA) are gaining significant attention as promising molecules for RNA-based vaccines and therapeutics.

However, the development of circRNA and saRNA faces numerous CMC challenges, including impurity removal in circRNA production (e.g., precursor RNA and nicked RNA), process scalability, integrity analysis for both circRNA and saRNA, and effective encapsulation strategies.

Innoforce’s RNA Center of Excellence is dedicated to achieving scalable, high-quality production of RNA molecules, including mRNA, circRNA, and saRNA, through advanced process development and optimization. Leveraging extensive platform development and project execution experience, they have successfully addressed critical process and analytical challenges to support the development of vaccines and therapeutics.

Key Takeaways:

Register or Login and hit Watch Now to view the recorded webcast now.